
The objectives of this phase I study were to determine the maximum tolerated dose zzso toxicity profile, and zzso of a 24-hour continuous intravenous infusion of zzso administered to children and adolescents with zzso or relapsed solid zzso 

Patients between the ages of 4 and 16 years old with zzso solid tumors received zzso as a 24-hour infusion every 21 zzso zzso and zzso growth factor support were administered with each zzso zzso studies were conducted during cycle zzso 

Patients zzso zzso zzso median zzso age zzso zzso years received zzso at zzso zzso zzso zzso zzso zzso zzso zzso or zzso zzso zzso 3) zzso At the zzso zzso dose level, one patient had dose limiting anorexia and zzso At zzso zzso two patients experienced dose limiting zzso dehydration, and zzso zzso zzso zzso limiting zzso included elevated serum zzso zzso zzso zzso and zzso Plasma zzso parameters were similar to historical data in zzso One partial response was observed in a patient with neuroendocrine zzso zzso disease zzso zzso was achieved in three patients zzso zzso zzso 2, zzso small round cell tumor zzso zzso zzso 

The zzso of zzso in pediatric patients with zzso solid tumors is zzso zzso IV over 24 hours every 21 zzso zzso to zzso zzso toxicity and zzso growth factor support are zzso 

